Cocrystal Pharma’s (COCP) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP) in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock.

Cocrystal Pharma Stock Performance

Shares of COCP stock opened at $2.00 on Wednesday. The stock has a fifty day simple moving average of $2.16 and a two-hundred day simple moving average of $1.99. The firm has a market capitalization of $20.35 million, a PE ratio of -1.08 and a beta of 1.53. Cocrystal Pharma has a 52-week low of $1.33 and a 52-week high of $3.26.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.